Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions.
Saigusa, R
Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions. [electronic resource] - The British journal of dermatology Feb 2016 - 338-47 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1365-2133
10.1111/bjd.14183 doi
Adult
Aged
Analysis of Variance
Animals
Antigens, CD--physiology
Bleomycin--pharmacology
Bosentan
Case-Control Studies
Cells, Cultured
Down-Regulation--physiology
Endothelial Cells--metabolism
Endothelial Protein C Receptor
Endothelin Receptor Antagonists--pharmacology
Endothelium, Vascular--metabolism
Enzyme-Linked Immunosorbent Assay
Female
Fibrinolysin--drug effects
Humans
Male
Mice
Microvessels--metabolism
Middle Aged
Proto-Oncogene Protein c-fli-1--deficiency
Receptors, Cell Surface--physiology
Scleroderma, Systemic--blood
Sulfonamides--pharmacology
Thrombophilia--etiology
alpha-2-Antiplasmin--drug effects
Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions. [electronic resource] - The British journal of dermatology Feb 2016 - 338-47 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1365-2133
10.1111/bjd.14183 doi
Adult
Aged
Analysis of Variance
Animals
Antigens, CD--physiology
Bleomycin--pharmacology
Bosentan
Case-Control Studies
Cells, Cultured
Down-Regulation--physiology
Endothelial Cells--metabolism
Endothelial Protein C Receptor
Endothelin Receptor Antagonists--pharmacology
Endothelium, Vascular--metabolism
Enzyme-Linked Immunosorbent Assay
Female
Fibrinolysin--drug effects
Humans
Male
Mice
Microvessels--metabolism
Middle Aged
Proto-Oncogene Protein c-fli-1--deficiency
Receptors, Cell Surface--physiology
Scleroderma, Systemic--blood
Sulfonamides--pharmacology
Thrombophilia--etiology
alpha-2-Antiplasmin--drug effects